Yoshinobu Onuma

A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods

Patrick W. Serruys, John A. Ormiston, Yoshinobu Onuma et al. · The Lancet · 2009 · 816 citations

Percutaneous Coronary Intervention, Cardiovascular Translational Research, Cardiovascular Disease +10

Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II

Vasim Farooq, David van Klaveren, Ewout W. Steyerberg et al. · The Lancet · 2013 · 813 citations

Cardiac Surgery, Percutaneous Coronary Intervention, Cardiovascular Disease +11

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Pascal Vranckx, Marco Valgimigli, Peter Jüni et al. · The Lancet · 2018 · 761 citations

Endovascular Technique, Cardiovascular Disease, Randomised Superiority Trial +8

A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial

John A. Ormiston, Patrick W. Serruys, Evelyn Regar et al. · The Lancet · 2008 · 714 citations

Percutaneous Coronary Intervention, Prospective Open-label Trial, Cardiovascular Disease +6

Assessment of the SYNTAX score in the Syntax study

Patrick Serruys, Yoshinobu Onuma, Scot Garg et al. · EuroIntervention · 2009 · 635 citations